Concepts and experimental models derived from basic research have been successfully applied to the field of molecular oncology, tremendously increasing our knowledge of the nature and the progression of tumors. The process of epithelial-to-mesenchymal transition, the cancer stem cell hypothesis, and their functional association and interdependence represent some of the most significant examples. The molecular determinants underlying the plasticity of cancers are currently the object of extensive research efforts, and a substantial body of evidence suggests that these models can be connected by the regulatory role of microRNAs, small noncoding RNA molecules with a fundamental role in many cellular functions. This review will highlight and discuss this link and its possible implications for the fight against cancer.
INTRODUCTION
The epithelial-to-mesenchymal transition (EMT) is a cellular differentiation process that determines cancer plasticity. 1 Tumors that undergo EMT can increase both invasion and metastasis formation, and have been found to generate cells with the properties of cancer stem cells (CSCs), populations within tumors believed to be responsible for some of the most malignant features of cancer, including phenotypic and behavioral heterogeneity, dormancy and chemoresistance. [2] [3] [4] MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate the expression of target genes through specific base-pairing interactions, and they have been found to have a fundamental role in many aspects of tumorigenesis. 5 Some miRNAs can efficiently regulate EMT and tumor differentiation; these include members of the miR-200, let-7, miR-34 and miR-302 families. 6 These miRNAs have also been functionally linked to CSCs, and represent new, promising targets for cancer therapy. A better understanding of how miRNAs drive or suppress EMT, and the functional mechanisms behind the generation and maintenance of cells with stem-like properties could pave the way for novel and more effective therapeutic approaches.
EMT AND CANCER
Normal epithelia possess cell-to-cell contacts that are responsible for the maintenance of homeostasis and architecture of epithelial structures. During carcinogenesis, epithelial tumor cells typically lose their epithelial-like characteristics and acquire a less differentiated phenotype with motile behavior. Such phenotypic conversion is reminiscent of the so-called EMT arising during embryonic life at precise times and locations, which is a fundamental developmental process by which cells dissociate from their epithelial tissues of origin and migrate. 7 EMT is associated with the loss of intercellular junctions, the loss of epithelial polarity and the increase in cell motility. 8 For this reason,
EMT is thought to have a fundamental role during the early steps of tumorigenesis, invasion and metastasis of carcinoma cells. During the last two decades, EMT has gained wide recognition as a mechanism involved in tumor progression that has great potential as a therapeutic target. EMT can be initiated by signals originating from outside the epithelial cell. Extracellular matrix components (that is, collagen), soluble factors, including epidermal growth factor, scatter factor/ hepatocyte growth factor, and members of the fibroblast growth factor and transforming growth factor-b (TGF-b) families have been shown to be directly involved in the induction of this process. 9 Among these, a major role in EMT is played by TGF-b, a secreted protein that controls proliferation and cellular differentiation. The TGF-b signaling pathway is SMAD and RAS/ RAF/MEK/MAPK dependent in various epithelial cell types, 8 and can activate down-stream events leading to EMT.
The mechanisms by which epithelial cells can be transformed into fibroblast-like cells may be divided in two distinct biological events, which may occur simultaneously in the cells: cell-cell dissociation (achieved primarily through the downregulation of E-cadherin) and cell movement, driven by cytoskeletal remodeling (for example, mediated by intermediate filament proteins such as vimentin) and the formation of new cell-matrix contacts. 7 The transition is characterized by a comprehensive switch in the gene expression profile, with the loss of proteins characteristic of polarized epithelial cells, and the synthesis of proteins associated with a mesenchymal phenotype. 10 Motile fibroblast-like cells activate molecular programs capable of simultaneous degradation and de novo synthesis of extracellular matrix, which allows them to invade through basement membranes and continue migration. 8 
MECHANISMS OF E-CADHERIN REGULATION
In recent years, many transcriptional mechanisms have been shown to be responsible for the EMT conversion. Among these, the transcriptional repression of E-cadherin has been identified as a crucial process in EMT, and is vital for initiating metastatic spread. E-cadherin (gene name CDH1, also known as CD324) is a transmembrane adhesion molecule belonging to the CAM family of proteins that forms adherens junctions by Ca 2 þ -dependent homophilic interactions. With respect to the regulation of cancer progression and metastasis, E-cadherin is considered to be a tumor suppressor gene. 11 Its downregulation, in fact, decreases the strength of cellular adhesion within a tissue, allowing cancer cells to cross the basement membrane and invade surrounding tissues. The negative prognostic value of loss of E-cadherin protein expression in cancer has been extensively documented, being generally correlated with poor differentiation, lymph node involvement and metastatic spread. [12] [13] [14] [15] Multiple mechanisms of E-cadherin dysregulation have been identified in cancer, the most extensively studied being mutations and transcriptional repression by promoter hyper-methylation.
Transcriptional repression of E-cadherin is achieved by several transcriptional factors, including SNAIL, SLUG, TWIST, ZEB1 and ZEB2 (also called SIP-1), all of which are zinc-finger or basic helixloop-helix proteins that interact with the proximal E-boxes of the E-cadherin promoter (as recognition sites). 16 Overexpression of these factors downregulates the expression of E-cadherin messenger RNA (mRNA) and protein, whereas their inhibition in epithelial cancer cell lines lacking E-cadherin protein restores the expression of the E-cadherin gene. [17] [18] [19] [20] The upregulation of vimentin, a type III intermediate filament protein that is expressed in mesenchymal cells and which contributes to the metastatic conversion of epithelial cancer cells, can also be regulated by ZEB2. 21 However, not all of these EMT regulators are simultaneously present and active in a tumor cell, nor are all linked to E-cadherin expression, and their pattern of expression can be different for every histological type of tumor. 22 As another mechanism of E-cadherin regulation, transcriptional downregulation by promoter methylation has been observed and related to EMT and increased invasiveness in breast, 23 prostate 24 and other solid tumors, mostly correlating with an adverse prognosis for the patient. 25 In addition, other mechanisms of epigenetic control, such as covalent histone modifications and deregulation of chromatin remodeling complexes, also regulate the process of EMT through the regulation of E-cadherin. 26, 27 Finally, mutations of the E-cadherin gene are also seen in cancer in the absence of a link to tumor progression or impact on prognosis. 23, 28 Mesenchymal-to-epithelial transition (MET), the reverse process of EMT, also occurs during embryogenesis 29 and its potential role in the metastatic spread of cancer has been highlighted. 30, 31 A recently proposed model suggested that EMT in cancer may not be an irreversible process, and that MET could be responsible for reepithelialization, during the metastasis formation, once the cancer cells have reached a suitable environment for their growth at a distant site. 31 As described, increase in E-cadherin levels in lymph node metastases relative to matched primary tumor samples and the observed morphological similarity between primary tumors and metastatic lesions are supporting this model. 32 More recently, an experimental mouse model of breast cancer identified a powerful role of MET in metastatic colonization, through the activity of miRNAs. 33 In conclusion, multiple mechanisms of E-cadherin regulation are critical drivers of EMT, which is a finely regulated (potentially reversible) developmental program that can allow carcinoma cells to switch between various differentiation stages, conferring substantial plasticity and aggressiveness. This regulation contributes to local invasion and metastatic spread of solid tumors. 34, 35 Because of their huge impact in many cellular processes and in many pathological conditions including cancer, miRNAs have been extensively studied since their discovery in the early 1990s. miRNAs are first transcribed by RNA polymerase II as parts of longer molecules, up to several kilobases in length (pri-miRNA), that are processed in the nucleus into hairpin RNAs of 70-100 nt by the ribonuclease Drosha. The resulting hairpin pre-miRNAs are then transported to the cytoplasm by the nuclear transport factor exportin 5 and further processed by the ribonuclease Dicer. In animals, single-stranded miRNAs are assembled into RNA-induced silencing complexes, and primarily bind target mRNA at specific sequence motifs (seed matches) predominantly found in the 3 0 untranslated region of the transcript. Seed matches are highly, but not completely, complementary to the miRNA. The mRNA/miRNA duplex can suppress translation either through an mRNA 5' capdependent mechanism affecting initiation or by transcript degradation. 36 miRNAs have been shown to be deregulated in virtually all types of cancer. They have a key role in important aspects of tumorigenesis, such as initiation, tumor growth, progression and differentiation, mainly by interfering with the expression of genes involved in key processes, including cell cycle, apoptosis and cell migration. Studies that compared miRNA expression in normal and tumor tissues demonstrated global alterations in miRNA expression levels in various human malignancies. 37 Consequently, miRNAs have been demonstrated to act either as oncogenes (for example, miR-155, miR-17-5p, miR-21) or as tumor suppressors (for example, miR-34, miR-15a, miR-16-1, let-7). Moreover, similar to conventional genes, miRNA expression can be altered by various mechanisms, including genetic and epigenetic alterations.
In practice, miRNA expression can be quantified by real-time PCR or by various hybridization techniques including northern blotting, which can be sensitive and accurate. Because of their ability to target multiple transcripts, miRNAs can be powerful biomarkers, and their expression has already been correlated with the clinical outcome of cancer patients in numerous tumor types. Their detection (either directly in the cancerous tissues or in other body fluids, such as blood plasma samples) is currently under investigation as a promising prognostic and diagnostic tool. 5 
miRNAs CONTROL CANCER PLASTICITY AND EMT
A strong connection between miRNAs, cancer plasticity and EMT has been established. One of the first miRNAs to be identified (in Caenorhabditis elegans) is the ubiquitously expressed let-7/miR-98 family, which in humans, includes 13 members located on 9 different chromosomes. 38, 39 Let-7 has an important role during embryonic development, and its expression is found frequently downregulated in several cancer types. It can prevent tumorigenesis by directly targeting genes like HMGA2 and IMP-1 40 that are expressed in embryos or fetuses and then downregulated or undetectable in adult normal tissues, but which are reexpressed in tumors, so-called oncofetal genes, as well as other oncogenes including the members of Ras family 41 and c-MYC.
42,43
Importantly, one of these oncogenes, the RNA-binding protein LIN28B, can interfere with the processing of let-7 family members, repressing the expression of mature let-7 in cells. This LIN28B/let-7 axis has a crucial role in controlling carcinogenesis and tumor progression. 44 The first evidence that miRNAs can act as regulators of EMT came in 2008, when four reports from different institutions demonstrated a role of the miR-200 family in the control of the epithelial/mesenchymal phenotype of cancer cells. [45] [46] [47] [48] Although these investigators approached the question from different angles and used different methodologies, they came to the conclusion that the miR-200 family is both a marker and a powerful regulator of EMT in cancer. In these studies and in subsequent work, forced overexpression of miR-200 through pre-miRNA transfection into mesenchymal-like cancer cells was able to alter the morphology of the cells, and to successfully inhibit in vitro migration and invasion. In contrast, reduction or loss of cellular miR-200, which downregulated E-cadherin and upregulated vimentin, resulted in a more mesenchymal-like, highly motile and aggressive phenotype of cancer cells. In some cancer types its loss has been frequently associated with increased promoter methylation, 50 and has been generally associated with a less differentiated phenotype and higher motility/ invasiveness. 45, 46, 48, 49, [51] [52] [53] The miR-200 family members can also be trans-activated by p53 in a mechanism of EMT suppression regulated by ZEB1.
54 ZEB1 has also been described as able to directly suppress the transcription of miR-200 family members via a negative feed-back loop that it is thought to stabilize EMT and to promote the invasion of cancer cells. 48 A similar mechanism of mutual inhibition was shown for miR-200 and another transcription factor, the GATA-binding factor GATA3 in the control of EMT and metastasis in a lung adenocarcinoma mouse model. 53 Despite this convincing evidence regarding the role of the miR-200 family in EMT in the context of tumorigenesis, the function of miR-200 in cancer is far from understood. Initial data, which quickly led to the hypothesized role of miR-200 as a metastasis suppressing miRNA, were unexpectedly contradicted by subsequent findings demonstrating that miR-200 could enhance cancer cell colonization in the formation of distant metastases in a mouse model of breast cancer. 55 Moreover, a number of conflicting results appeared in the literature indicating a lack of general consensus as to whether miR-200 was up-or downregulated in advanced or metastasizing cancers, as observed in the case of ovarian cancer. [56] [57] [58] [59] Although some of these inconsistencies might be explained by technical issues, such as different methods of sample collection and RNA extraction, it was hypothesized that these discrepancies were a consequence of the nature of miR-200 to be either up-or downregulated during cancer, depending on the stage of progression. 6 A recent report has shed some light on this matter, confirming a pro-metastatic role for miR-200 in a clinical and experimental model of breast cancer metastasis. 33 In this study, overexpression of miR-200 was found to promote metastatic colonization, in part by targeting the secretion of metastasissuppressive proteins. In light of these recent data, miR-200 should be viewed as a master regulator of cancer cell plasticity, rather than a dedicated metastasis suppressor miRNA. Thus, miR-200 is downregulated in cancer cells during the process of local invasion and intravasation during EMT, and is subsequently reexpressed when the cells re-epithelialize through the reverse process, MET, and colonize local or distant tissues. This alternative model, although introducing a higher level of complexity, could also help to explain some of the inconsistencies regarding miR-200 expression observed in clinical studies.
In addition to the members of the miR-200 family, other miRNAs regulate the process of EMT through regulation of critical EMT 60 miR-30 61 and miR-138. 62 The miR-34 family, which includes three members, miR-34a, b, and c, localized to two distinct genomic loci, is a p53 transcriptional target whose overexpression triggers cell cycle arrest or apoptosis in a cell-type-and context-dependent manner. Similar to miR-200, miR-34 can also be inhibited by ZEB1, which drives pro-metastatic remodeling of cytoskeletal actin required for tumor cell invasion.
63 miR-34 was also shown to regulate EMT through a double-negative feedback loop with the transcription factor SNAIL. 60 Another EMT-regulating miRNA is miR-138. In squamous cell carcinoma cell lines, miR-138 has been shown to regulate EMT by three distinct mechanisms: by direct control of vimentin expression, by targeting of ZEB2 and via the epigenetic regulator enhancer of zeste homolog 2 (EZH2), 62 which was shown to suppress E-cadherin and induce EMT through histone methylation. 27 Another miRNA positively correlated with EMT is miR-155, the transcription of which is promoted by TGF-b through SMAD4, and its knockdown has been shown to suppress TGF-b-induced EMT, and migration and invasion in normal murine mammary epithelial cells. 64 In conclusion, miRNAs can be added to the list of regulatory elements that control the EMT process of cancer cells, and represent potential biomarkers of cancer plasticity and tumor progression.
THE ROLE OF miRNAs IN CSCS
Tumors are frequently composed of heterogeneous populations of cells, and this feature is believed to be responsible for some of their most lethal properties, such as becoming refractory to chemo/radiotherapy causing patients to relapse after therapy. Although the hierarchical structure of cancer and the ways by which heterogeneity is achieved and maintained is still the object of an intense debate, and different explanations and models have been proposed for several tumor types, the presence of a defined population of cells, known as CSCs or tumor-initiating cells, which possess the capacity to self-renew and to generate a differentiated progeny (through asymmetric division) and to efficiently seed tumors, is now well established. 2, 4, [65] [66] [67] miRNAs have a central role in stem cell biology; they regulate key features of stem cells such as self-renewal, pluripotency and differentiation. 68 The importance of miRNAs in stem cells is underscored by the observation that complete ablation of miRNAs by disrupting Dicer in mouse embryonic stem cells generates cells with severe defects in differentiation. 69 Among the miRNAs, best correlating with a stem cell property is miR-34, which has been recently described as a powerful barrier against somatic cell reprogramming, a process by which somatic cells can be converted into pluripotent cells that functionally resemble embryonic stem cells. Upon p53 activation, miR-34 represses specific cell-cycle genes, including cyclin D1, cyclin E2, CDK4, CDK6 and pluripotency genes, including NANOG, SOX2, and N-MYC, 70 even though it was subsequently demonstrated that cells isolated from miR-34a/b/c-deficient mice did not show impaired p53-mediated responses and that the mice developed normally, indicating the presence of alternative pathways. 71 In cancer cells, miRNAs have a similar role in the control of CSC expansion. In this scenario, miR-34 overexpression was found to suppress the tumorinitiating cell population significantly inhibiting tumor-spheres growth in vitro and reducing tumor formation in vivo in a prostate cancer model. 72 Owing to its importance in the control of tumor differentiation, another miRNA family with a critical role in CSCs is let-7. Its expression is found in differentiated cells but is lost in stem cells. 73 In breast cancer, let-7 members have been found to be depleted in CSCs isolated from patients who had received chemotherapy, and were found to be markedly increased when the cells were exposed to differentiation-inducing conditions. 74 Consistent with these observations, the top three let-7 target genes that we miRNAs regulate EMT and CSCs P Ceppi and ME Peter identified, HMGA2, IMP-1 and LIN28B, have all been reported to be important in stem cells and to not be expressed in differentiated cells. 40 miR-200 members, which directly target the self-renewal regulator polycomb ring finger oncogene BMI1, 75 have been found to be highly downregulated in human breast CSCs as compared with non-tumorigenic cancer cells. miR-200c, in particular, was shown to inhibit the clonal expansion of CSCs in vitro, and to reduce the ability of normal mammary stem cells to form mammary ducts in vivo. 75 Consistently, an inducible model for CSC formation showed strong inhibition of all members of miR-200 family (as well as of let-7 members). In particular, inhibition of miR-200b, which is responsible for regulating the expression of SUZ12, a subunit of a polycomb repressor complex (PRC2) required for mammosphere growth, was observed leading to E-cadherin repression, increasing migration and CSC growth. 76 In contrast to these miRNAs that are found to be downregulated in CSCs, the miR-302/367 cluster of miRNAs was found to be abundantly expressed in CSCs, and to be strongly repressed during differentiation. This cluster is coded on human chromosome 4 and consists of nine different miRNAs co-transcribed in a polycistronic manner. 77 The miR-302/367 family was shown to be upregulated when somatic cells acquire a pluripotent embryonic stem-like state. 78 miR-302/367 family members are regulated by the stem cell transcription factors OCT4 and SOX2. Interestingly, overexpression of miR-302 alone is enough to reprogram various somatic cells into induced pluripotent stem cells. 79 To explore the importance of miRNAs in the biology of CSCs, their expression was profiled in CSCs from different cancer types using microarray approaches. Although current data are limited, the first evidence generally confirms data from functional studies indicating that some common pathways regulated by miRNAs are critical for CSCs. However, cancer-specific differences were found. In breast cancer cell lines, miRNA profiling of CSCs identified miR-375, miR-203 and miR-200c as downregulated, and miR-221 and miR-222 (which share the same seed match and the same chromosomal localization) and miR-100 and miR-125b as the most significantly upregulated. 80 In prostate cancer cell lines, miR-34a, let-7b, miR-106a and miR-141 were found to be absent in CSCs, whereas miR-301 and miR-452 were found to be upregulated. 81 In the ovarian cancer cell line OVCAR-3, a significant downregulation of miR-9, miR-100, miR-200c and miR-223 was detected among CD133-positive CSCs as compared with CD133-negative cells, whereas miR-204 and miR-206 were found to be upregulated in CD133-positive cells and downregulated in CD133-negative cells. 82 In the colorectal carcinoma cell line DLD1, expression profiling of colonospheres versus parental cells indicated that miR455p and miR-675 were upregulated, whereas miR-146, miR-223, miR-451 and miR-144 (the latter two belonging to the same cluster) were significantly downregulated. In the same report, a role for miR-451 was identified in the control of self-renewal, tumorigenicity in mice and chemo-resistance through an indirect regulation of cyclooxygenase-2 transcription. 83 The results from these and other studies reporting profiles of miRNA expression in CSCs from different cancer types are listed in Supplementary  Table 1 , identifying the most highly up-and downregulated miRNAs in each analysis, and some of the miRNAs that are specific to different cancer types.
In conclusion, miRNAs are emerging as important markers and key regulators of CSCs by suppressing CSC-specific genes and activities, including self-renewal, sphere formation and tumorigenicity, and they could be potentially used to distinguish CSCs from differentiated populations.
THE FUNCTIONAL LINK BETWEEN miRNAs, EMT AND CSCS
The first evidence that EMT might be linked to CSCs came from data indicating that cells undergoing EMT contained an increased population of cells with stem-like properties. Immortalized normal and transformed human mammary epithelial cells, in which EMT was induced by overexpression of EMT-promoting transcription factors or by TGF-b treatment, acquired CSC markers, and an increased ability to grow in mammospheres cultures, in soft-agar plates and to form tumors in mice. 84 Based on these results, the unidirectionality of the differentiation process in the standard view of the hierarchical organization of tumors according to the CSC model (that is, from undifferentiated to differentiated cells) began to be questioned, and a new model of organization suggesting a more dynamic equilibrium between CSC and non-CSC pools in cancers was proposed. 67 Consistent with this view, subsequent data, most of which focused on breast cancer, demonstrated the interconversion of CSCs and non-CSCs, 85, 86 and highlighted the role of EMT in this process. 87 Analysis of the contextual signals that promote EMT, migration and the growth of breast CSCs (as mammospheres) from human mammary epithelial cells revealed that autocrine signals, involving both TGF-b and the canonical and non-canonical Wnt pathways, were required 88 (see Figure 1) . The single-cell dynamics of phenotypic CSC-to-non-CSC interconversions have also been recently described in breast cancer cell lines. Once separated, distinct populations revealed a similar tendency to return to a pre-existing equilibrium of different states. This process has been mathematically modeled and validated as being stochastically determined (that is, the transition probabilities are independent of the previous states), and these findings shed some light on the mechanisms behind breast cancer heterogeneity. 85 In breast and prostate cancer cells, the spontaneous conversion of non-CSCs to CSCs was found to be more inefficient than the reciprocal conversion, and to be accelerated by interleukin-6 treatment. 89 Some of the observations connecting EMT and the generation of CSCs have been independently confirmed in other cancer types. Recent evidence showed that EMT induced by TGF-b can promote the formation of lung cancer stem/progenitor cells (PCs) expressing the cancer stem markers ALDH1 and CD133, and that PCs and non-PCs are also interconvertible. 90 In head and neck cancer, a functional role for Src kinase in the modulation of selfrenewal, stem-related genes, EMT transformation and invasion was recently established through a pathway that functionally involves CD133. 91 CSC-related proteins can also be transcriptionally activated directly by transcription factors responsible for EMT, as shown for the self-renewal factor BMI1 in concert with TWIST1 in a pathway that leads to EMT induction and tumor initiation. 92 In ovarian cancer, CSCs isolated from cell lines were shown to upregulate EMT genes and to downregulate epithelial and pro-apoptotic genes. 93 In prostate cancer cells, it was shown that EMT induced by stable overexpression of platelet-derived growth factor D conferred a stem-like phenotype, and enhanced clonogenic and sphere-forming ability and tumorigenicity of cells in mice. 94 The authors also found evidence of a mechanistic connection between EMT and the self-renewal properties of prostate cancer cells and miR-200 and let-7 family members.
Because of its powerful role as an EMT regulator, miR-200 has taken center stage as a regulator of cancer plasticity and CSCs. A specific role was reported for the tumor suppressor p53, which can transactivate miR-200c through direct binding to the miR200c promoter, acting in a regulatory role in breast cancer EMT and CSCs. 95 Moreover, it was recently shown that long-term mammosphere cultures of MCF-7 cells (which express high levels of miR-200s) can give rise through EMT to a stable population of mesenchymal-like cells, in which analysis of miRNA expression indicated a systematic loss of miR-200c. 96 As a further link between miRNAs, EMT and CSCs in breast cancer, a loss of heterozygosity of human chromosome 3p (observed in 87% of clinical specimens of primary breast cancers), which results in the depletion of miR-128-2 expression, resulted in the lack of suppression of several targets, including BMI1, LIN28A, NANOG, miRNAs regulate EMT and CSCs P Ceppi and ME Peter KLF4 and SNAIL, with known direct roles in EMT and CSCs. SNAIL was also shown to directly suppress miR-128-2 expression upon TGF-b stimulation in a feedback loop that drives oncogenic transformation. 97 In hepatocellular carcinomas, the frequently downregulated miR-214 was found to target EZH2 and b-catenin, suppressing tumor growth and invasion, and inducing the expression of E-cadherin. Interestingly, inhibition of miR-214 expression also resulted in an increase of EpCAM-positive cells, which are known to be liver cancer CSCs. 98 An opposite role for the same miRNA has been reported in ovarian CSCs. Previously associated with chemoresistance and with high-grade and late-stage tumors, 99 miR-214 was also shown to repress p53 and regulating the pluripotency gene NANOG. 100 In endometrial carcinoma, reduction of BMI1 expression after targeting miR-194 was shown to reduce invasion and to promote MET, as well as to decrease the expression of stem cell and chemo-resistance markers, including SOX-2, KLF4 and MRP-1. 104 Moreover, an interesting crosstalk between hyaluronan and its receptor, the stem cell marker CD44, was recently shown to stimulate miR-21 expression, PDCD4 downregulation and to increase the chemo-resistance of head and neck squamous cell carcinoma cells through a NANOG/ STAT3 signaling cascade. 105 An interesting link between EMT and the stem cell marker miRNA family miR-302/369 was recently reported. In general, the initiation phase in the reprogramming path to pluripotency seems to have parallels with the process of MET, the reverse of EMT, with the involvement of miR-200. 106 Consequently, miR-200c, in combination with miR-302 and miR-369, was recently successfully used to reprogram mouse and human cells. 107 miR-302/369 cluster members have also been shown to directly target critical EMT genes such as TGF-b receptors or the Ras homolog family member C (RHOC), the inhibition of which enhanced the reprogramming of mouse fibroblast into pluripotent stem cells. 108 miRNAs that have been found to connect EMT and CSCs in various cancer types are presented in Table 1 .
In contrast to the data linking EMT to CSCs in various cancers, recent observations based on prostate and bladder cancer models have demonstrated that the self-renewal properties and metastatic phenotype in certain cancers require the maintenance of an epithelial, rather than mesenchymal, program. 109 It was demonstrated that the cooperation of mesenchymal-like tumor cell subpopulations enhances the local invasiveness of epithelial cells. Although these results seem to contradict the emerging literature, and challenge the concept of EMT as promoting rather than suppressing cancer stemness, they probably reflect the limitations of simplified models to describe complex systems. Some of the observed inconsistencies may be related to specific cell types and tumor origins. Together, the data point to a need for more comprehensive tumor models, which also include key players of the tumor microenvironment including stromal and other non-tumor cells that promote invasion and CSC formation.
POSSIBLE APPLICATIONS AND FUTURE PERSPECTIVES
One interesting and potentially therapeutically relevant implication of the link between miRNAs and CSCs concerns chemoresistance of cancer cells. CSCs have been consistently identified, and in some cases even defined and isolated, as the population within a tumor with the lowest sensitivity to treatment with standard chemotherapeutic agents, and EMT itself has been shown to strongly contribute to cancer drug resistance. 3 As documented in multiple publications, drug resistant cancer cells have stem cell traits, and the number of CSCs in cell lines can be miRNAs regulate EMT and CSCs P Ceppi and ME Peter increased by treating them with chemotherapy and/or radiation in vitro or in vivo. In addition, the number of CSCs is increased in cancer patients following chemotherapy. 74, 131, 137 In some cases, the exposure of cancer cells to escalating concentrations of chemotherapeutic drugs has been shown to correlate with CSC formation and with the induction of EMT through the downregulation of miRNAs. 74, 138, 139 This particular property of CSCs, together with possible mechanisms of clonal selection and dormancy, could explain the frequent relapse of tumors with increased aggressiveness and chemo-resistance commonly observed in the clinic. In line with this, it is not surprising that powerful tumor suppressor miRNAs connected to CSCs, such as miR-200 and let-7, have been described as chemosensitizers, or have been shown to carry predictive value for response to therapy in different cancer types in both pre-clinical and clinical settings. 49, [140] [141] [142] Examples include miR-200, which restored the sensitivity of bladder cancer cells to epidermal growth factor receptor inhibitors, 143 and let-7, which modulated the resistance of ovarian cancer to Taxanes. 140 These findings open the fascinating possibility of exploring 'miRNA replacement' or 'miRNA antisense targeting' as a novel approach to overcoming therapy resistance of cancer. Early attempts to use tumor-suppressor miRNAs in mouse models have been promising, and warrant further implementations. [144] [145] [146] [147] The screening and synthesis of small-molecule inhibitors specific for each miRNA may also represent a valid approach toward inhibiting therapeutically relevant miRNAs. 148 Such agents could, in the future, be used in combination with standard chemotherapeutic agents to block the up-or downregulation of miRNAs associated with therapy resistance.
Another important implication of the emerging body of literature on the connection between miRNA and CSCs lies in the use of miRNAs as biomarkers. CSCs are currently being identified and tracked in three different ways: (1) through surface markers, 149 which include CD133, CD117, CD44, CD24, CD90 and aldehyde dehydrogenase 1 (ALDH1). [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] (2) Through isolation from spheres (that is, mammo-, neuro-or hepatospheres). [161] [162] [163] [164] (3) Through isolation from side populations. This latter method is based on the observation that CSCs exclude the DNA-binding dye Hoechst 33342 because of the overexpression of ABC transporters such as ABCG2, which makes them appear in flow cytometry to be less intensely stained. 165, 166 However, as reviewed recently by others, each of these methods has its caveats, and none of them can be used to selectively track CSCs. 2, 4, [167] [168] [169] The Hoechst dye used to isolate side population cells is toxic to cells; tumor spheres cannot be reliably obtained from all cancer cells, and are usually only partially enriched in CSCs, and surface markers tend to be specific and different for each cancer type making them not useful as universal CSC markers. In addition, surface markers are expressed by normal tissue stem cells, which hampers separation of CSCs from normal stem cells. Finally, a recent broad evaluation of several putative stem cell markers in the 60 cell lines maintained by the NCI (NCI-60 cells) revealed a general lack of correlation between the pattern of expression of these candidate markers and the tumorigenic capacity of the cells. 170 In consideration of the attendant difficulties associated with the current methods to isolate and enrich CSCs, and based on the special role of miRNAs in CSCs, it is possible that CSCs could be isolated by using a combination of specific miRNA biosensors. Such miRNA reporters have been used to track expression of individual miRNAs inside cells. 73, [171] [172] [173] [174] [175] [176] [177] In human embryonic stem cells, this system has been recently implemented and used to monitor the expression of miRNAs during the generation and differentiation of human induced pluripotent stem cells into multilineage embryoid bodies. 175 Toward the goal of using these sensors as general tools to isolate CSCs, we are currently developing dual activity miRNA biosensors that will allow tracking of at least two miRNAs and miRNA families simultaneously in living cells.
In conclusion, recent data have connected the activity of miRNAs with two key processes-EMT and the generation and maintenance of CSCs-that contribute to cancer formation, progression, metastasis and therapy resistance. A better understanding of how miRNAs drive or suppress EMT and, thereby, the stemness of cancer cells is the basis upon which to develop new therapeutic approaches that will eventually impact clinical practice. Abbreviations: CSC, cancer stem cell; EMT, epithelial-to-mesenchymal transition; miRNA, microRNA.
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